Article Text

Download PDFPDF

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
  1. N I Cherny1,
  2. R Sullivan2,
  3. U Dafni3,
  4. J M Kerst4,
  5. A Sobrero5,
  6. C Zielinski6,
  7. M J Piccart7,
  8. J Bogaerts8,
  9. J Tabernero9,
  10. N J Latino10,
  11. E G E de Vries11
  1. 1Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel
  2. 2Kings Health Partners Integrated Cancer Centre, Kings College London, Institute of Cancer Policy, London, UK
  3. 3University of Athens and Frontiers of Science Foundation-Hellas, Athens, Greece
  4. 4Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Netherlands Cancer Institute, Amsterdam, The Netherlands
  5. 5Department of Medical Oncology, IRCCS San Martino IST, Genova, Italy
  6. 6Division of Oncology, Medical University Vienna, Vienna, Austria
  7. 7Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium
  8. 8EORTC HQ, Brussels, Belgium
  9. 9Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
  10. 10European Society for Medical Oncology, Viganello-Lugano, Switzerland
  11. 11Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
  1. Correspondence to N J Latino, ESMO Head Office, via Luigi Taddei 4, 6962 Viganello - Lugano, Switzerland; mcbs{at}esmo.org

Abstract

The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a standardised, generic, validated tool to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies. The ESMO-MCBS is intended to both assist oncologists in explaining the likely benefits of a particular treatment to their patients as well as to aid public health decision makers' prioritise therapies for reimbursement. From its inception the ESMO-MCBS Working Group has invited questions and critiques to promote understanding and to address misunderstandings regarding the nuanced use of the scale, and to identify shortcomings in the scale to be addressed in future planned revisions and updates. The ESMO-MCBS V.1.0 has attracted many questions regarding its development, structure and potential applications. These questions, together with responses from the ESMO-MCBS Working Group, have been edited and collated, and are herein presented as a supplementary resource.

  • Methodically validity
  • Health technology assessment
  • MCBS
  • ESMO

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.